GLP-1 drugs could help prevent 34,000 heart attacks and strokes in the US each year, research suggests
CNN
Certain blockbuster weight-loss drugs have been found to protect the heart in significant ways, and new research suggests that the cardiovascular benefits could extend to an even broader set of patients than clinical trial data has shown – helping prevent tens of thousands of heart attacks and strokes each year in the United States.
Certain blockbuster weight-loss drugs have been found to protect the heart in significant ways, and new research suggests that the cardiovascular benefits could extend to an even broader set of patients than clinical trial data has shown – helping prevent tens of thousands of heart attacks and strokes each year in the United States. Clinical trial data from drugmaker Novo Nordisk showed that people using Wegovy had a 20% lower risk of a cardiac event than those who got a placebo. In March, the US Food and Drug Administration approved a change that added cardiovascular benefits to Wegovy’s label, making it the first weight-loss drug to be cleared to reduce the risk of heart attack, stroke or heart-related death in people at higher risk of these conditions. Wegovy is part of a class of drugs called GLP-1 receptor agonists, and its active ingredient, semaglutide, is also approved to treat type 2 diabetes as Ozempic. Novo Nordisk’s trial was limited to people living with obesity who had a previous heart attack or stroke, or symptoms of peripheral artery disease such as clogged arteries in the arms or legs. New research from Dandelion Health, a platform that uses real-world data and clinical AI to advance personalized care, found that GLP-1 drugs could also serve as primary prevention, significantly reducing risk for people with mild or moderate cardiovascular disease who hadn’t had a cardiac event. With the help of artificial intelligence, researchers analyzed real-world medical records for a set of patients who were similar to those enrolled in the Novo Nordisk clinical trial but without the history of a major adverse cardiovascular event.
Evidence is mounting that the wildly popular weight-loss medicines known as GLP-1s may also hold potential for treating addiction, and the field may be on the verge of obtaining desperately needed answers through more study.
Known for her blistering pace and powerful shots, the soccer player is having a Barbie made in her likeness as the toymaker names her as role model of the year.
The Screen Actors Guild Awards are back with a new name — and a thematic dress code.
There’s growing concern that the US Department of Health and Human Services is abandoning the US Preventive Services Task Force – or pushing it into “quiet paralysis.”
An international meeting to determine the status of measles elimination in the United States has been delayed seven months, from its original date in mid-April until sometime in November.
When she was in her 40s Jenny Teeters had a serious secret drinking problem, but, she says, her success hid it exceptionally well for years. At one point she managed a high six-figure tech job, raised two teenage girls, finished her MBA, and taught Zumba in her spare time and somehow she did it all while intoxicated.But she got to a place where she knew she needed help, and like with what a new study found, she found what finally made her sobriety stick was developing a newfound faith in a higher power.
Gucci’s new designer Demna embraces the technology, with uneven results.
Next winter Burberry wants you out on the town, whatever the weather.
The US has recorded more than 1,100 measles cases so far this year, according to data published Friday by the US Centers for Disease Control and Prevention. It’s a troubling milestone that has many in public health bracing for the worst.